INFU · Infusystem Holdings, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.68M | - | $36.49M | $36.00M | $34.72M | - | $35.32M | $33.70M | $32.00M | - |
| Cost of Revenue | $14.00M | - | $15.67M | $16.13M | $15.55M | - | $16.27M | $17.03M | $15.52M | - |
| Gross Profit | $19.68M | - | $20.82M | $19.87M | $19.17M | - | $19.05M | $16.67M | $16.47M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $14.80M | - | $14.43M | $13.15M | $15.32M | - | $12.78M | $11.52M | $13.70M | - |
| Total Operating Expenses | $18.09M | - | $17.01M | $16.10M | $18.55M | - | $15.78M | $14.81M | $17.32M | - |
| D&A | $3.25M | - | $3.28M | $3.34M | $3.32M | - | $3.15M | $3.03M | $2.90M | - |
| Operating Income | $1.59M | - | $3.81M | $3.78M | $618.0K | - | $3.27M | $1.85M | ($845.0K) | - |
| Interest Expense | $255.0K | - | $330.0K | $373.0K | $456.0K | - | $476.0K | $484.0K | $456.0K | - |
| Income Tax | $400.0K | - | $1.17M | $847.0K | $520.0K | - | $978.0K | $591.0K | ($186.0K) | - |
| Net Income | $1.02M | - | $2.26M | $2.60M | ($267.0K) | - | $1.81M | $717.0K | ($1.11M) | - |
| EPS - Basic | $0.05 | - | $0.11 | $0.12 | ($0.01) | - | $0.08 | $0.03 | ($0.05) | - |
| EPS - Diluted | $0.05 | - | $0.11 | $0.12 | ($0.01) | - | $0.08 | $0.03 | ($0.05) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.11M | $3.19M | $955.0K | $720.0K | $1.51M | $527.0K | $380.0K | $146.0K | $822.0K | $231.0K |
| Accounts Receivable | $23.98M | $22.90M | $24.31M | $24.48M | $23.89M | $21.16M | $22.76M | $21.32M | $20.54M | $19.83M |
| Inventory | $5.83M | $5.39M | $5.59M | $5.67M | $6.09M | $6.53M | $6.70M | $6.84M | $6.25M | $6.40M |
| Accounts Payable | $9.63M | $10.82M | $10.02M | $9.32M | $8.37M | $9.85M | $8.91M | $9.94M | $9.80M | $8.01M |
| Current Assets | $36.66M | $36.34M | $35.57M | $34.80M | $35.32M | $32.16M | $33.61M | $32.91M | $32.46M | $30.62M |
| Total Assets | $98.66M | $100.56M | $98.88M | $100.85M | $104.28M | $103.61M | $105.30M | $108.53M | $104.85M | $102.92M |
| Current Liabilities | $17.14M | $20.18M | $18.72M | $15.86M | $15.97M | $17.66M | $16.94M | $15.88M | $17.31M | $15.71M |
| Long-term Debt | $19.65M | $19.63M | $20.93M | $26.35M | $28.71M | $23.86M | $27.98M | $34.16M | $29.93M | $29.10M |
| Total Liabilities | $39.91M | $43.23M | $43.41M | $46.31M | $49.13M | $46.09M | $49.79M | $55.04M | $52.57M | $50.61M |
| Stockholders' Equity | $58.75M | $57.33M | $55.47M | $54.53M | $55.15M | $57.53M | $55.51M | $53.49M | $52.28M | $52.30M |
| Retained Earnings | ($60.54M) | ($60.70M) | ($61.43M) | ($61.52M) | ($60.62M) | ($57.46M) | ($58.19M) | ($59.30M) | ($59.74M) | ($58.63M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $970.0K | - | - | - | $1.78M | - | - | - | $377.0K | - |
| Investing Cash Flow | ($1.26M) | - | - | - | ($2.66M) | - | - | - | ($418.0K) | - |
| Financing Cash Flow | ($790.0K) | - | - | - | $1.86M | - | - | - | $632.0K | - |
| CapEx | $157.0K | - | - | - | $131.0K | - | - | - | $182.0K | - |
| Free Cash Flow | $813.0K | - | - | - | $1.65M | - | - | - | $195.0K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 58.4% | - | 57.1% | 55.2% | 55.2% | - | 53.9% | 49.5% | 51.5% | - |
| Operating margin | 4.7% | - | 10.4% | 10.5% | 1.8% | - | 9.2% | 5.5% | -2.6% | - |
| EBITDA margin | 14.4% | - | 19.4% | 19.8% | 11.3% | - | 18.1% | 14.5% | 6.4% | - |
| Net margin | 3.0% | - | 6.2% | 7.2% | -0.8% | - | 5.1% | 2.1% | -3.5% | - |
| Free cash flow margin | 2.4% | - | - | - | 4.7% | - | - | - | 0.6% | - |
| FCF / Net income | 0.80 | - | - | - | -6.18 | - | - | - | -0.18 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 43.9% | - | 39.5% | 36.5% | 44.1% | - | 36.2% | 34.2% | 42.8% | - |
| Effective tax rate | 28.2% | - | 34.1% | 24.6% | 205.5% | - | 35.1% | 45.2% | - | - |
| Return on assets | 1.0% | - | 2.3% | 2.6% | -0.3% | - | 1.7% | 0.7% | -1.1% | - |
| Return on equity | 1.7% | - | 4.1% | 4.8% | -0.5% | - | 3.3% | 1.3% | -2.1% | - |
| Return on invested capital | 1.5% | - | 3.3% | 3.5% | 0.4% | - | 2.5% | 1.2% | -0.8% | - |
| Liquidity | ||||||||||
| Current ratio | 2.14 | 1.80 | 1.90 | 2.19 | 2.21 | 1.82 | 1.98 | 2.07 | 1.87 | 1.95 |
| Quick ratio | 1.80 | 1.53 | 1.60 | 1.84 | 1.83 | 1.45 | 1.59 | 1.64 | 1.51 | 1.54 |
| Cash ratio | 0.12 | 0.16 | 0.05 | 0.05 | 0.09 | 0.03 | 0.02 | 0.01 | 0.05 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | 0.33 | 0.34 | 0.38 | 0.48 | 0.52 | 0.41 | 0.50 | 0.64 | 0.57 | 0.56 |
| Debt / Assets | 0.20 | 0.20 | 0.21 | 0.26 | 0.28 | 0.23 | 0.27 | 0.31 | 0.29 | 0.28 |
| Debt / EBITDA | 4.06 | - | 2.95 | 3.70 | 7.29 | - | 4.36 | 6.99 | 14.56 | - |
| Interest coverage | 6.2x | - | 11.5x | 10.1x | 1.4x | - | 6.9x | 3.8x | -1.9x | - |
| Equity multiplier | 1.68 | 1.75 | 1.78 | 1.85 | 1.89 | 1.80 | 1.90 | 2.03 | 2.01 | 1.97 |
| Liabilities / Assets | 0.40 | 0.43 | 0.44 | 0.46 | 0.47 | 0.44 | 0.47 | 0.51 | 0.50 | 0.49 |
| Efficiency | ||||||||||
| Asset turnover | 0.34 | - | 0.37 | 0.36 | 0.33 | - | 0.34 | 0.31 | 0.31 | - |
| Inventory turnover | 2.40 | - | 2.80 | 2.85 | 2.55 | - | 2.43 | 2.49 | 2.48 | - |
| Days sales outstanding | 260d | - | 243d | 248d | 251d | - | 235d | 231d | 234d | - |
| Days inventory outstanding | 152d | - | 130d | 128d | 143d | - | 150d | 147d | 147d | - |
| Days payable outstanding | 251d | - | 234d | 211d | 196d | - | 200d | 213d | 230d | - |
| Cash conversion cycle | 161d | - | 140d | 166d | 198d | - | 186d | 165d | 151d | - |
| Valuation | ||||||||||
| P / E | 184.6x | - | 94.2x | 52.0x | - | - | 83.8x | 227.7x | - | - |
| P / B | 3.3x | - | 3.9x | 2.4x | 2.1x | - | 2.6x | 2.8x | 3.5x | - |
| P / S | 5.7x | - | 5.9x | 3.6x | 3.3x | - | 4.1x | 4.4x | 5.7x | - |
| EV / EBITDA | 43.4x | - | 33.4x | 22.1x | 35.8x | - | 26.9x | 37.3x | 102.7x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -3.0% | - | 3.3% | 6.8% | 8.5% | - | 10.7% | 6.2% | 5.4% | - |
| Revenue CAGR (3y) | 3.5% | - | 10.2% | 10.0% | 9.1% | - | 10.0% | 10.7% | 9.4% | - |
| Revenue CAGR (5y) | 6.6% | - | 7.7% | 6.7% | 10.0% | - | 10.4% | 11.3% | 12.0% | - |
| Gross profit growth (YoY) | 2.7% | - | 9.3% | 19.2% | 16.3% | - | 17.2% | 1.4% | 6.0% | - |
| Operating income growth (YoY) | 157.3% | - | 16.7% | 103.6% | - | - | 92.4% | 48.6% | -689.7% | - |
| Net income growth (YoY) | - | - | 25.0% | 262.5% | 76.0% | - | 162.3% | 64.8% | -243.2% | - |
| EPS growth (YoY) | - | - | 37.5% | 300.0% | 80.0% | - | 166.7% | 50.0% | -150.0% | - |
| EPS CAGR (3y) | - | - | 76.5% | - | - | - | - | -9.1% | - | - |
| EPS CAGR (5y) | - | - | -4.7% | -8.8% | - | - | 9.9% | - | - | - |
| FCF growth (YoY) | -50.7% | - | - | - | 745.6% | - | - | - | - | - |
| FCF CAGR (5y) | -17.5% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 6.5% | -0.4% | -0.1% | 2.0% | 5.5% | 10.0% | 7.9% | 7.1% | 8.3% | 9.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$263.71M totalPatient Services And Device Solutions$113.08M · 42.9%
Patient Services$86.53M · 32.8%
Device Solutions$64.10M · 24.3%
Product / service
$39.92M totalThird Party Payer Rentals$17.75M · 44.5%
Service$11.83M · 29.6%
Direct Payer Rentals$7.75M · 19.4%
Product$2.59M · 6.5%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing InfuSystem Holdings against the 5 most active filers in the same SIC group.